Latest news with #warrants
Globe and Mail
2 days ago
- Business
- Globe and Mail
Enovix Distributes Dividend of Warrants to Stockholders
FREMONT, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX) ('Company' or 'Enovix'), a global high-performance battery company, today announced that it will distribute warrants to purchase Enovix common stock ('Warrants') to its shareholders and certain convertible noteholders on Monday, July 21, 2025 (the 'Distribution Date'), in accordance with the previously declared shareholder warrant dividend. As previously announced, each stockholder of record as of July 17, 2025 (the 'Record Date') will receive one (1) Warrant for every seven (7) shares of Enovix common stock held, rounded down to the nearest whole Warrant. 'The distribution of these warrants reflects our confidence in the long-term value we're building at Enovix as we scale production and deliver breakthrough battery performance,' said Raj Talluri, President and CEO of Enovix. 'It's been incredibly rewarding to see such a positive response from our diverse shareholder base, including both retail and institutional investors, which reinforces our belief that this approach puts shareholders first, where they belong.' The Warrants will be distributed by the Company's warrant agent and will be exercisable for cash following the Distribution Date, in accordance with the terms of the warrant agreement, a form of which was filed as an exhibit to the Form 8-A Warrant registration statement with the U.S. Securities and Exchange Commission on July 18, 2025. Warrant Terms Eligibility: Shareholders must have purchased or held shares no later than July 16, 2025 to be a shareholder of record on the July 17, 2025 Record Date and receive Warrants. Ratio: One (1) Warrant for every seven (7) shares of common stock held as of the Record Date, rounded down to the nearest whole number for any fractional Warrant. No fractional Warrants will be issued. Example: A shareholder holding 1,000 shares will receive 142 Warrants. A shareholder holding 7,000 shares will receive 1,000 Warrants. Convertible Noteholders: Holders of Enovix's 3.00% Convertible Senior Notes due 2028 (the 'Convertible Notes') as of the Record Date will also receive Warrants based on the same ratio. Example: Holders of each $1,000 face amount of Convertible Notes will receive 9.1543 Warrants, rounded down to the nearest whole number for any fractional Warrant. Expiration: The Warrants will expire at 5:00 p.m. New York City time on October 1, 2026, unless an early expiration price condition is triggered. Early Expiration Price Condition: If, during any 20 (whether or not consecutive) out of 30 consecutive trading days, the volume-weighted average price (VWAP) of Enovix common stock equals or exceeds $10.50 (the 'Early Expiration Trigger Price'), the Warrants will expire at 5:00 p.m. New York City time on the business day immediately following the final qualifying day (or another date the Company may select in accordance with the warrant agreement). Exercisability: The warrants are exercisable at any time through the Expiration Date. Early Expiration Condition Timing In keeping with our commitment to shareholder communication, Enovix notes that its common stock closed at $15.54 on July 18, 2025. Under the terms of the warrant agreement, if the VWAP of Enovix common stock equals or exceeds $10.50 for any 20 (whether or not consecutive) out of 30 trading days following the Distribution Date, the Warrants will expire at 5:00 p.m. New York City time on the business day immediately following the final qualifying day. If our stock continues to trade above the $10.50 threshold, and the early expiration price condition is met without interruption, the Warrants could expire as early as August 19, 2025. The Company makes no prediction or assurance regarding the future performance of its stock price and encourages all warrant holders to review the warrant agreement and consult their financial advisors regarding the timing and mechanics of warrant exercises. Resources Shareholders are encouraged to review the information available on the Company's Warrant Dividend Resource Page, which includes the Investor FAQ Supplement, and to contact their broker directly with any questions. About Enovix Corporation Enovix is a leader in advancing lithium-ion battery technology with its proprietary cell architecture designed to deliver higher energy density and improved safety. The Company's breakthrough silicon-anode batteries are engineered to power a wide range of devices from wearable electronics and mobile communications to industrial and electric vehicle applications. Enovix's technology enables longer battery life and faster charging, supporting the growing global demand for high-performance energy storage. Enovix holds a robust portfolio of issued and pending patents covering its core battery design, manufacturing process, and system integration innovations. For more information, visit Forward‐Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and can be identified by words such as anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, possible, potential, predict, should, will, would, and similar expressions that convey uncertainty about future events or outcomes. Forward-looking statements in this press release include, without limitation, statements regarding the Company's expectations related to the warrant dividend including that the distribution is a shareholder-first approach, the Company's ability to build long-term value, scale production and deliver breakthrough battery performance, the Company's ability to implement its business strategy, and the Company's broader business outlook. Actual results and outcomes could differ materially from those expressed in these forward-looking statements due to various risks and uncertainties, including those discussed in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of Enovix's most recently filed annual report on Form 10-K and quarterly reports on Form 10-Q and other documents filed with the Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date on which they are made or released. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Yahoo
5 days ago
- Business
- Yahoo
Smith Micro Announces Closing of Follow-On Offering
PITTSBURGH, July 18, 2025--(BUSINESS WIRE)--Smith Micro Software, Inc. (the "Company" or "Smith Micro") (Nasdaq: SMSI) today announced the closing of its offering of 1,612,903 registered shares of its common stock (together with accompanying unregistered warrants) at a price of $0.93 per share to certain institutional and accredited investors pursuant to a definitive agreement with the investors. The warrants entitle the holders to purchase up to an aggregate of 1,612,903 shares of the Company's common stock at an exercise price of $1.20 per share (subject to certain downward pricing adjustments, including anti-dilution protection). The warrants were issued to the investors in a private placement, are immediately exercisable and will expire five years after issuance. The offering and concurrent private placement resulted in gross proceeds to the Company of approximately $1.5 million prior to fees and offering expenses. The Company intends to use the proceeds of the registered offering and concurrent private placement for working capital and general corporate purposes. Chardan served as financial advisor to the Company in connection with the registered offering and concurrent private placement. Buchanan Ingersoll & Rooney PC served as legal counsel to the Company in the transactions, while Haynes and Boone, LLP served as legal counsel to the investors. A shelf registration statement on Form S-3, File No. 333-287029, relating to the registered offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and declared effective on May 16, 2025. A prospectus supplement describing the terms of the registered offering and the accompanying base prospectus were filed with the SEC and are available for free on the SEC's website located at The offering of the common stock in the registered offering was made only by means of a prospectus. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered offering, when available, may be obtained by contacting: Smith Micro Software, Inc., 5800 Corporate Drive, Pittsburgh, PA 15237 Attn: Investor Relations, telephone: 412-837-5300, or by email at ir@ The warrants were offered and sold in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. Accordingly, the warrants and underlying shares of common stock issuable upon exercise of the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file registration statements with the SEC registering the resale of the shares of common stock issuable upon exercise of the unregistered warrants issued in connection with the private placement concurrent with the registered offering. This press release is not an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Smith Micro Software, Inc. Smith Micro develops software to simplify and enhance the mobile experience, providing solutions to some of the leading wireless service providers around the world. From enabling Digital Family Lifestyle™ solutions to providing powerful voice messaging capabilities, our solutions enrich today's connected lifestyles while creating new opportunities to engage consumers via smartphones and consumer IoT devices. For more information, visit Smith Micro and the Smith Micro logo are registered trademarks or trademarks of Smith Micro Software, Inc. Forward-Looking Statements Certain statements in this release are forward-looking statements regarding future events or results within the meaning of the Private Securities Litigation Reform Act, including statements related to the Company's market and other conditions; the ability of the Company to satisfy its post-closing obligations in connection with the offering; the anticipated use of proceeds from the offering; and other statements using such words as "expect," "anticipate," "believe," "plan," "intend," "could," "may," "will" and other similar expressions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in the forward-looking statements, including risks and uncertainties related to market conditions, the satisfaction of offering-related contractual post-closing obligations in connection with the transactions, and the use of proceeds from the offering. These and other factors discussed in our filings with the Securities and Exchange Commission, including our filings on Forms 10-K and 10-Q, could cause actual results to differ materially from those expressed or implied in any forward-looking statements. The forward-looking statements contained in this release are made on the basis of the views and assumptions of management, and we do not undertake any obligation to update these statements to reflect events or circumstances occurring after the date of this release. View source version on Contacts PR/IR INQUIRIES: Charles MessmanInvestor Relations(949) 362-2306IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Smith Micro Announces Closing of Follow-On Offering
PITTSBURGH, July 18, 2025--(BUSINESS WIRE)--Smith Micro Software, Inc. (the "Company" or "Smith Micro") (Nasdaq: SMSI) today announced the closing of its offering of 1,612,903 registered shares of its common stock (together with accompanying unregistered warrants) at a price of $0.93 per share to certain institutional and accredited investors pursuant to a definitive agreement with the investors. The warrants entitle the holders to purchase up to an aggregate of 1,612,903 shares of the Company's common stock at an exercise price of $1.20 per share (subject to certain downward pricing adjustments, including anti-dilution protection). The warrants were issued to the investors in a private placement, are immediately exercisable and will expire five years after issuance. The offering and concurrent private placement resulted in gross proceeds to the Company of approximately $1.5 million prior to fees and offering expenses. The Company intends to use the proceeds of the registered offering and concurrent private placement for working capital and general corporate purposes. Chardan served as financial advisor to the Company in connection with the registered offering and concurrent private placement. Buchanan Ingersoll & Rooney PC served as legal counsel to the Company in the transactions, while Haynes and Boone, LLP served as legal counsel to the investors. A shelf registration statement on Form S-3, File No. 333-287029, relating to the registered offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and declared effective on May 16, 2025. A prospectus supplement describing the terms of the registered offering and the accompanying base prospectus were filed with the SEC and are available for free on the SEC's website located at The offering of the common stock in the registered offering was made only by means of a prospectus. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered offering, when available, may be obtained by contacting: Smith Micro Software, Inc., 5800 Corporate Drive, Pittsburgh, PA 15237 Attn: Investor Relations, telephone: 412-837-5300, or by email at ir@ The warrants were offered and sold in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. Accordingly, the warrants and underlying shares of common stock issuable upon exercise of the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file registration statements with the SEC registering the resale of the shares of common stock issuable upon exercise of the unregistered warrants issued in connection with the private placement concurrent with the registered offering. This press release is not an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Smith Micro Software, Inc. Smith Micro develops software to simplify and enhance the mobile experience, providing solutions to some of the leading wireless service providers around the world. From enabling Digital Family Lifestyle™ solutions to providing powerful voice messaging capabilities, our solutions enrich today's connected lifestyles while creating new opportunities to engage consumers via smartphones and consumer IoT devices. For more information, visit Smith Micro and the Smith Micro logo are registered trademarks or trademarks of Smith Micro Software, Inc. Forward-Looking Statements Certain statements in this release are forward-looking statements regarding future events or results within the meaning of the Private Securities Litigation Reform Act, including statements related to the Company's market and other conditions; the ability of the Company to satisfy its post-closing obligations in connection with the offering; the anticipated use of proceeds from the offering; and other statements using such words as "expect," "anticipate," "believe," "plan," "intend," "could," "may," "will" and other similar expressions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in the forward-looking statements, including risks and uncertainties related to market conditions, the satisfaction of offering-related contractual post-closing obligations in connection with the transactions, and the use of proceeds from the offering. These and other factors discussed in our filings with the Securities and Exchange Commission, including our filings on Forms 10-K and 10-Q, could cause actual results to differ materially from those expressed or implied in any forward-looking statements. The forward-looking statements contained in this release are made on the basis of the views and assumptions of management, and we do not undertake any obligation to update these statements to reflect events or circumstances occurring after the date of this release. View source version on Contacts PR/IR INQUIRIES: Charles MessmanInvestor Relations(949) 362-2306IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
16-07-2025
- Business
- Globe and Mail
Netcapital Announces Up To $5.9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$3 million upfront with up to an additional $2.9 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants Boston, July 16, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (the 'Company') (NASDAQ: NCPL, NPCLW), a digital private capital markets ecosystem, today announced that it has entered into definitive agreements for the purchase and sale of 641,712 shares of common stock at a purchase price of $4.675 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 641,712 shares of common stock at an exercise price of $4.55 per share that will be immediately exercisable upon issuance and will expire twenty-four months following the effective date of the registration statement covering the resale of the shares of common stock issuable upon exercise of the unregistered short-term warrants. The closing of the offering is expected to occur on or about July 17, 2025 subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $3 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the unregistered short-term warrants, if fully-exercised on a cash basis, will be approximately $2.9 million. No assurance can be given that any of such unregistered short-term warrants will be exercised. The Company intends to use the net proceeds from the offering for the repayment of certain outstanding promissory notes and for general working capital purposes. The common stock (but not the unregistered short-term warrants and the shares of common stock underlying the unregistered short-term warrants) described above are being offered by the Company pursuant to a 'shelf' registration statement on Form S-3 (File No. 333-267921) that was declared effective by the Securities and Exchange Commission (the 'SEC') on October 26, 2022. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@ The unregistered short-term warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered short-term warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered short-term warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Netcapital Inc. Netcapital Inc. is a fintech company with a scalable technology platform that allows private companies to raise capital online and provides private equity investment opportunities to investors. The Company's consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies. The Company's funding portal, Netcapital Funding Portal Inc. is registered with the U.S. Securities & Exchange Commission (SEC) and is a member of the Financial Industry Regulatory Authority (FINRA), a registered national securities association. The Company's broker-dealer, Netcapital Securities Inc., is also registered with the SEC and is a member of FINRA. Forward Looking Statements The information contained herein includes forward-looking statements. These statements relate to future events, including, but not limited to, statements relating to closing of the offering and satisfaction of closing conditions of the offering, the expected gross proceeds from the offering, the exercise of the unregistered short-term warrants prior to their expiration and statements regarding the anticipated use of proceeds from the offering, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Yahoo
16-07-2025
- Business
- Yahoo
Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants will have an exercise price of $1.32 per share, will be immediately exercisable upon issuance, and will expire five years from the date of issuance. Gross proceeds from the offering, before deducting placement agent fees and other estimated offering expenses, are expected to be approximately $9.0 million. Maxim Group LLC is acting as sole placement agent in connection with the offering. The Company intends to use the net proceeds from the offering primarily to support the commercialization of LYMPHIR, including milestone, royalty, or other payments pursuant to existing license agreements, as well as for working capital and general corporate purposes. The offering is expected to close on or about July 17, 2025, subject to the satisfaction of customary closing conditions. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-288656), as amended, which was filed with the U.S. Securities and Exchange Commission ("SEC") on July 14, 2025, and was declared effective by the SEC on July 16, 2025. A final prospectus relating to the offering will be filed with the SEC, and once available, may be obtained on the SEC's website at The offering is being made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering, when available, may also be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, Attention: Syndicate Department, by telephone at (212) 895-3745 or by email at syndicate@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Citius Oncology, Inc. Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit About Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price, and includes all statements related to the completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of net proceeds from the offering. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: risks related to the closing of the offering; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our need for substantial additional funds; Citius Pharma's ability to maintain compliance with Nasdaq's continued listing requirements; the estimated markets for our product candidates and the acceptance thereof by any market; our ability to successfully implement and maintain distribution agreements with current or other future distribution partners; potential disruptions or performance issues involving third-party logistics providers; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at including in Citius Oncology's Annual Report on Forms 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as amended on January 27, 2025, and as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allenir@ x113 Media Contact: STiR-communicationsGreg SalsburgGreg@ View original content to download multimedia: SOURCE Citius Oncology, Inc. Sign in to access your portfolio
